June Off to a Poor ...
Health Care: Drugs
AVANIR Pharmaceuticals (AVNR: NASDAQ)
$2.82 -0.15 | -5.05%
06/01/12 - 04:00 PM ET
Company Income Statement
| Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | |
| Sales | 10.50M | 2.90M | 4.18M | 6.96M |
| Cost of Sales | 8.14K | -7.36K | -177.42K | 532.37K |
| Gross Operating Profit | 10.49M | 2.90M | 4.35M | 6.43M |
| Selling, General, and Administrative Expenses | 55.43M | 16.47M | 10.15M | 10.60M |
| Research & Development | 15.25M | 13.32M | 15.87M | 14.11M |
| Operating Income before D & A (EBITDA) | -60.19M | -26.89M | -21.66M | -18.28M |
| Depreciation & Amortization | 437.84K | 205.00K | 260.78K | 678.76K |
| Interest Income | 38.78K | 15.02K | 204.19K | 1.28M |
| Other Income - Net | -37.73K | 390.76K | -271.82K | 2.31M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -60.63M | -26.69M | -21.99M | -15.37M |
| Interest Expense | 0.00 | 0.00 | 517.00 | 540.62K |
| Pre-Tax Income | -60.63M | -26.69M | -21.99M | -15.91M |
| Income Taxes | 3.20K | 3.20K | 3.20K | 3.20K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -60.63M | -26.69M | -22.00M | -15.91M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | -1.58M |
| Net Income From Total Operations | -60.63M | -26.69M | -22.00M | -17.50M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -60.63M | -26.69M | -22.00M | -17.50M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-60.63M | -26.69M | -22.00M | -15.91M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -60.63M | -26.69M | -22.00M | -15.91M |
| Basic EPS from Continuing Ops. | -0.51 | -0.30 | -0.28 | -0.27 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | -0.03 |
| Basic EPS from Total Operations | -0.51 | -0.30 | -0.28 | -0.30 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.51 | -0.30 | -0.28 | -0.30 |
| Basic Normalized Net Income/Share | -0.51 | -0.30 | -0.28 | -0.27 |
| EPS fr Continuing Ops. | -0.51 | -0.30 | -0.28 | -0.27 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | -0.03 |
| EPS fr Total Ops. | -0.51 | -0.30 | -0.28 | -0.30 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.51 | -0.30 | -0.28 | -0.30 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.51 | -0.30 | -0.28 | -0.27 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with AVNR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Most Shorted Stocks in B...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Biotech Drug-Launch Stock...
- ContributorBreakout Stocks Of The Week...
- UserMy Portfolio
- Contributor6 Heavily Shorted Stocks 04...
- Contributor5 Stocks With the Largest S...
- Usergm401
- Userparvardigar
Latest AVNR Headlines from TheStreet
- Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript) 05.17.12 | 05:05 pm
- Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 11:05 pm
- Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript 05.08.12 | 03:05 pm
- Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript 02.29.12 | 01:02 pm
- AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript 02.07.12 | 10:02 pm
- Friday's Top 10 Articles, Videos on TheStreet 01.20.12 | 02:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- AVANIR Stock Hits New 52-Week Low (AVNR) 12.14.11 | 03:12 pm
- Avanir's CEO Discusses Q4 2011 Results - Earnings Call Transcript 12.12.11 | 11:12 pm
- Biotech Stock Mailbag: 2011 Report Card 11.25.11 | 05:11 am
Press Releases for AVNR
- Avanir Pharmaceuticals To Present At Jefferies 2012 Global Healthcare Conference - PR Newswire 05.29.12 | 08:05 am
- Avanir Pharmaceuticals To Present Data At The American Academy Of Neurology Annual Meeting - PR Newswire 04.17.12 | 08:04 am
- Avanir Pharmaceuticals To Present At BioCentury Future Leaders In The Biotech Industry Conference - PR Newswire 04.10.12 | 08:04 am
- Avanir Pharmaceuticals Announces Appointment Of Rohan Palekar As Chief Commercial Officer - PR Newswire 03.16.12 | 08:03 am
- Avanir Pharmaceuticals To Participate In Two Conferences In March - PR Newswire 03.01.12 | 04:03 pm
- Avanir Pharmaceuticals To Participate In Citi 2012 Global Health Care Conference - PR Newswire 02.21.12 | 09:02 am
- Avanir Pharmaceuticals Announces Publication Of Phase III Study Results Showing Efficacy And Safety Of AVP-923 In The Treatment Of Diabetic Neuropathic Pain - PR Newswire 02.08.12 | 09:02 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2012 First Quarter Financial Results And Conference Call - PR Newswire 01.30.12 | 08:01 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2011 Fourth Quarter And Year End Financial Results And Conference Call - PR Newswire 12.06.11 | 08:12 am
- Avanir Pharmaceuticals To Participate In Piper Jaffray Health Care Conference - PR Newswire 11.22.11 | 08:11 am
Partner Headlines for AVNR
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Avanir Pharmaceuticals: Limelight On The Horizon - Seeking Alpha 02.17.12 | 06:02 am
- Canaccord Reiterates Buy, $6 PT on Avanir Pharmaceuticals - Benzinga 11.30.11 | 09:11 am
- Avanir - Closing Short Position - Seeking Alpha 11.27.11 | 08:11 am
- 10 Small-Cap Stocks Deeply Undervalued By Target Price - Seeking Alpha 11.11.11 | 10:11 pm
- Avanir Pain Drug Should Provide Long-Term Growth - Seeking Alpha 09.30.11 | 06:09 pm
- Avanir: Congressional Inquiry Into the Pricing of Nuedexta Abandoned - Seeking Alpha 07.22.11 | 09:07 am
- Hearing Negative Chatter in Avanir Pharmaceuticals - Benzinga 06.30.11 | 01:06 pm
- Jefferies' Upadates - Benzinga 06.03.11 | 09:06 am
- Investors Should Take Notice of Congressional Questions Regarding Nuedexta Pricing - Seeking Alpha 05.27.11 | 09:05 am
